Ajanta Pharma revises Q1 FY27 earnings call time to 16:15 IST

Ajanta Pharma has revised the timing of its earnings conference call to discuss its Q1 FY27 unaudited financial results to 16:15 hrs IST on July 30, 2026. The leadership team will review the company's financial performance and take questions from investors. This discussion follows the company's board meeting and is conducted pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015.

Participants can join the discussion via specific dial-in numbers provided for domestic and international access. The company has also issued a Diamond pass link for faster connectivity, requiring prior registration to receive a calendar invite, passcode, and PIN. The passcode and PIN will be activated 30 minutes prior to the conference scheduled time.

Earnings Conference Call Details

Parameter	Details
Date	July 30, 2026
Time (IST)	16:15 – 17:15 hrs
Time (SST/HKT)	18:45 – 19:45 hrs
Time (BST)	11:45 – 12:45 hrs
Time (US ET)	06:45 – 07:45 hrs

Dial-in Information

Access Type	Contact Numbers
Universal Access (Primary)	+91 22 6280 1542, +91 22 7115 8372
USA (Toll Free)	18667462133
UK (Toll Free)	08081011573
Hong Kong (Toll Free)	800964448
Singapore (Toll Free)	8001012045

For those unable to attend the live session, a playback of the earnings call audio will be available 120 minutes after the conclusion of the event. Additionally, a full transcript of the conference call will be accessible on the company's official website.

1 Day	5 Days	1 Month	6 Months	1 Year	5 Years
-2.68%	+2.07%	+9.09%	+28.25%	+25.29%	+146.64%

Ajanta Pharma Ltd held its 47th Annual General Meeting (AGM) on July 16, 2026, through video-conferencing, approving all four resolutions listed on the agenda. The meeting adopted the audited standalone and consolidated financial statements for the financial year ended March 31, 2026. Shareholders also confirmed the interim dividend for the financial year ended March 31, 2026.

Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, the company submitted the voting results and the scrutinizer's report. The remote e-voting process was conducted via the NSDL platform from July 13, 2026, to July 15, 2026, for shareholders holding shares as on the record date of July 9, 2026. Mr. Pramod S. Shah & Associates, Practising Company Secretary, served as the scrutinizer for the e-voting process.

Voting Results Summary

The resolutions were passed with the requisite majority. The table below details the voting outcomes for each resolution:

Resolution Description	Votes For	Votes Against	% For	% Against
Adoption of Financial Statements FY26	111,336,195	5,305	99.9952	0.0048
Confirmation of Interim Dividend FY26	111,447,501	918	99.9992	0.0008
Reappointment of Director Mr. Mannalal Bhagwandas Agrawal	109,994,994	1,439,762	98.7080	1.2920
Ratification of Cost Auditors Remuneration FY27	111,433,629	1,112	99.9990	0.0010

Key Resolutions

Financial Statements and Dividend

The first ordinary resolution sought the adoption of the audited standalone and consolidated financial statements for the financial year ended March 31, 2026, along with the reports of the Board of Directors and Auditors. The second resolution confirmed the interim dividend for the financial year ended March 31, 2026.

Director Reappointment

A special resolution was passed to appoint a director in place of Mr. Mannalal Bhagwandas Agrawal (DIN: 00073828), who retires by rotation and offered himself for reappointment. This resolution received 98.7080% votes in favour.

Cost Auditor Ratification

The final ordinary resolution concerned the ratification of the remuneration of cost auditors for the financial year 2026-2027. This resolution was approved with 99.9990% of votes in favour.